HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions

May 21, 2024 |

2 min read

HighField Biopharmaceuticals announced that its abstract of preclinical data evaluating an mRNA-based GLP-1R agonist in diabetic monkeys has been accepted for a poster presentation at the American Diabetes Association 84th Scientific Sessions June 21-24, 2024, in Orlando, FL.

Filing of a U.S. IND for HFG1 is scheduled for Q3/2024

HANGZHOU, China--(BUSINESS WIRE)-- HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today that its abstract of preclinical data evaluating an mRNA-based GLP-1R agonist (HFG1) in diabetic monkeys has been accepted for a poster presentation at the American Diabetes Association (ADA) 84^th Scientific Sessions June 21-24, 2024, in Orlando, FL. The abstract also will be published on the website of the ADA’s journal Diabetes.

“We are very excited to introduce our unique lipid nanoparticle (LNP)-mRNA complex, HFG1, to the thousands of clinicians and researchers attending this year’s Scientific Sessions from around the world,” said HighField CEO and Scientific Founder Yuhong Xu, Ph.D. “The components of HFG1’s LNP complex were designed to provide consistent expression of a GLP-1R agonist for diabetes and weight loss. We believe HFG1 will require far fewer injections than existing GLP-1 products while providing steady-state agonist activity.”

Abstract Title:		Preliminary Study of Efficacy and Duration of an mRNA-Based GLP-1R Agonist in Diabetic Monkeys. (Poster presentation number 1860-LB in category 12-B Clinical Therapeutics-Incretin-Based Therapies).

Presenter:		Dr. Yuhong Xu, HighField CEO

Presentation:		Saturday, June 22, 2024, 12:30 pm – 1:30 pm EDT (The poster will be displayed Saturday, Sunday and Monday in the Poster Hall; and at a Networking Reception Friday evening.)

About HighField Biopharmaceuticals

HighField is a clinical stage company focused on novel applications of liposome constructs to disrupt existing immuno-oncology and other disease technologies. The company also has a research and development center and a GMP-compliant production facility. HighField’s lead clinical development program is HF1K16, a drug encapsulated immune modulating liposome containing all-trans retinoic acid targeting myeloid-derived suppressor cells for treatment of solid tumors. The company’s pipeline also includes drug encapsulated immunoliposomes for solid tumor cancers and lipid therapeutics for gene delivery and gene therapy. For more information visit https://highfield.bio.